What's breaking now, across thousands of outlets.
In recent trading, shares of Myriad Genetics, Inc. (Symbol: MYGN) have crossed above the average analyst 12-month target price of $3.31, changing hands for $3.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
The increase in Treasury yields triggered a sell-off of Asian and Australian bonds.
The really surprising thing is that it isn’t higher. People are finally losing faith in the European Union. That is one of the main findings of a survey by the European Council on Foreign Relations…
Two high-yield consumer stocks offer more income than Treasuries, but are the risks crushing their valuations as bad as investors think?
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price…
For years, Nigeria's insurance industry has struggled to expand at a pace commensurate with the size of the economy, remaining one of the smallest contributors to the nation's Gross Domestic Product…
Mumbai: Indian equity benchmarks closed lower on Friday but staged a recovery from their intraday lows as buying in information technology, FMCG and banking shares helped limit the damage amid weak…
